Informal two-component GH-axis combination label
CJC/IPA is a community label for CJC-1295 no DAC / Mod GRF(1-29) paired with ipamorelin. No verified trial of the combination was located. Published CJC-1295 DAC studies involve a different active moiety and cannot be transferred to this blend.
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Research at a glance
Depth and confidence summarize the research record—not effectiveness, safety, or a recommendation.
The available record consists of separate-component evidence and a documented absence of verified combination trials.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Different upstream receptors provide a rationale, but no direct evidence establishes synergy, compatibility, safety, or clinical benefit.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not a suggested amount.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: CJC-1295 DAC research concerns a different active moiety, while controlled ipamorelin evidence is intravenous and component-only. Neither can create SubQ blend instructions. Amounts shown describe cited research exposure—not a dosage recommendation.
Practical starting point
Common goals and questions—not recommendations or promises of benefit.
The overview, studies, and source ledger below explain what supports each label—and where the evidence stops.
What the evidence says
None for the combination, and no controlled human no-DAC CJC study was located. Ipamorelin has a 48-person intravenous hormone study; its 117-person intravenous Phase 2 trial did not demonstrate significant efficacy. CJC-1295 DAC findings concern a different active moiety.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
The no-DAC CJC salt and formulation, component ratio, compatibility, combined pharmacokinetics and GH/IGF-1 response, interactions, immunogenicity, repeated-use safety, and meaningful clinical outcomes.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
The evidence story
Importance shows how much an item changes the evidence story. Quality shows how much confidence the design deserves. A strong negative study can score highly on both.
Importance and quality answer different questions. A rigorous study can be highly important even when it challenges a popular claim.
A July 2026 PubMed and ClinicalTrials.gov audit found no verified controlled or registered study administering the defined no-DAC CJC/ipamorelin combination.
The primary endpoint was not significantly shorter with ipamorelin, and key secondary outcomes did not demonstrate significant efficacy.
CJC-1295 DAC produced sustained GH and IGF-1 changes in this small pharmacology program.
The trial was terminated and did not post results.
Ipamorelin produced a concentration-dependent short-term GH response.
Administration and handling
No controlled human administration study of the no-DAC CJC component was located, while controlled ipamorelin human studies used intravenous administration. CJC-1295 DAC protocols involve a different active moiety. No trial or approved label establishes a CJC/IPA route, dose, schedule, ratio, injection site, or reconstitution process.
No published compatibility or stability study was located for CJC-1295 no DAC / Mod GRF(1-29) and ipamorelin mixed together. Separate bulk-material observations or supplier instructions cannot establish blend identity, sterility, precipitation risk, aggregation risk, container compatibility, storage conditions, or beyond-use time.
Primary-source ledger
2026-07-25
2026-07-25
2026-01-01
2024-11-15
2024-09-27
2014-10-21 · PMID 25331030 · NCT00672074 · DOI 10.1007/s00384-014-2030-8
2006-03-01 · PMID 16352683 · DOI 10.1210/jc.2005-1536
2005-12-23 · NCT00267527
1999-09-01 · PMID 10496658 · DOI 10.1023/A:1018955126402